Co esponding au ho : Mohammad Khalid
Copy igh © 2025 Au ho (s) e ain he copy igh o his a icle. This a icle is published unde he e ms o he C ea i e Commons A ibu ion Liscense 4.0.
Monoclonal an ibodies: Pionee ing he u u e o medicine
Deepika Rajpu , Mohammad Khalid *, Shubham P a ap Singh, Megha Gup a and Anki Kuma
K ishna Pha macy College, Bijno , U a P adesh, India – 246701.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 083-087
Publica ion his o y: Recei ed on 15 No embe 2024; e ised on 29 Decembe 2024; accep ed on 31 Decembe 2024
A icle DOI: h ps://doi.o g/10.30574/wjbphs.2025.21.1.1074
Abs ac
La ge-scale manu ac u ing p ocedu es ha e been de eloped in esponse o he g owing demand o monoclonal
an ibodies (mAbs) u ilized in he apeu ic and diagnos ic applica ions. Con inuous op imiza ion o he unde lying
sys ems has imp o ed p oduc . Nume ous enhancemen s and changes o monoclonal an ibodies ha e been de ion. In
esponse o mAb limi a ions and side e ec s, he numbe o monoclonal an ibodies (mAbs) ha ha e p e iously been
app o ed o use in clinical ials and he apeu ic applica ions has expanded d ama ically in ecen yea s. These changes
ha e made i easie o employ mAbs in a a ie y o he apeu ic applica ions, including he managemen o in ec ious
diso de s b ough on by pa asi ic, bac e ial, i al, and ungal o ganisms. Addi ionally Monoclonal an ibodies ha e been
u ilized o ea Non-in ec ious diseases such as cance , immunological p oblems, and a h i is, , and p oblems caused
by o gan dona ion. This e iew looks a cu ing-edge echnology ela ed o he po en ial applica ion o mAbs in
biomedicine.
Keywo ds: Monoclonal an ibodies (mAbs); An ibody enginee ing; Humanized MAbs (HMAs); Ta ge an igen;
Radiolabeled an ibodies
1. In oduc ion
The in oduc ion o hyb idoma echnology in he 1970s led o he manu ac u e o huge olumes o monoclonal
an ibodies (mAbs) in a a ie y o o ms, including mu ine, chime ic, humanized, and comple ely human an ibodies. And,
mo e ecen ly, he u iliza ion o ecombinan DNA echnologies. These an ibodies a e a ailable o clinical use as highly
homogeneous speci ic eagen s (1-3). Some clinical s udies ha e examined pha macokine ics by quan i ying ac i i y
le els in no mal issues, moni o ing Blood ac i i y clea ance cu es and he a e o ac i i y exc e ion in u ine, as well
as, mos impo an ly, examina ion o plasma samples o de ec he molecula kinds o adioac i i y p esen (4-
6).Because o hei special quali ies, scien is s use hem o shield people om disease [7]. Because o his me hod, an
an ibody may ag an in ec ion o mic oo ganism, making i possible o o he immune sys em componen s o a ge i
and kill i di ec ly [8]. Changes o he Fab and Fc sec ions in luence he speci ici y, leng h, and ou come o he an ibody-
dependen esponse [9]. When Kohle and Mils ein c ea ed monoclonal an ibodies (MAbs) in 1975, hey ans o med
immunology. The i s Mab was ully licensed in 1986 [10].One signi ican achie emen has been he de elopmen o
MAbs in ansgenic plan s and animals [11]. The US Food and D ug Adminis a ion au ho ized he i s human
monoclonal an ibody o clinical use in 2002. The indus y ha p oduces mAbs has g own apidly since hen [12].
Recen ly, some 30 mAbs we e app o ed o use as ea men s in clinical se ings, and se e al mo e we e in a ious
phases o s udy [13].
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 083-087
84
1.1. Types o he apeu ic MAbs
Ad ances in an ibody enginee ing ha e p oduced a a ie y o mAbs o use in biomedicine and li e sciences. Despi e
ha ing di e en a ge s and uses, hese an ibodies may sha e simila concep s. Addi ionally, a numbe o conside a ions,
such as he applica ion’s goal, accessibili y, and e icacy, may in luence he decision o use one app oach o e ano he .
1.2. Mu ine Mab
Because humans and a s ha e di e en immune sys ems, mu ine an ibodies made using hyb idoma echnology ha e
limi ed uses in clinical medicine o human he apy. Excep in ex emely a e ci cums ances, his usually leads o
ea men ailu e [14]. Mu ine immunogenic componen s a e mo e success ully elimina ed when a a ie y o echniques
a e used o educe he immunogenic e ec s o mu ine monoclonal an ibodies in human he apy [15]. As a esul , he
mAb’s o e all immunogenici y is educed wi hou a ec ing he o iginal an ibody’s de ec ion abili y [16]. Humaniza ion-
de i ed an ibodies a e becoming inc easingly impo an in he ea men o cance and in lamma o y illnesses, wi h
many al eady on he ma ke and mo e in clinical ials[17].Chime ic an ibodies a e unique he apeu ic an ibody ypes
c ea ed by combining gene ic componen s om nonhuman animals (mice) and humans. They a e c ea ed by changing
mouse a iable a eas and human cons an egions [18]. Chime ic monoclonal an ibodies a e known by he su ix
“ximab,” such as In liximab, Ri uximab, and Abciximab [19].
Figu e 1 depic s he s eps in ol ed in Mab manu ac u ing
Humanized MAbs (HMAs) a e conside ed na u al pha maceu icals due o hei sa e y in i o ac ions. Human mAbs a e
now widely employed o disease he apy and immunodiagnos ics hanks o de elopmen s in mAb echnology. The e
a e app oxima ely 20 mAb medica ions, including humanized mice mAbs.
Figu e 2 The apeu ic Mab ypes and p oduc ion me hods
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 083-087
85
They ha e g own in popula i y as medicinal eagen s in ecen decades. O he monoclonal an ibodies a e in a ious
phases o clinical ials, unde he supe ision o di e en academic ins i u ions and/o in collabo a ion wi h
pha maceu ical companies. Human mAb echnologies a e ex emely use ul in heal h economics, in addi ion o s a egic
esea ch [20]. In e ms o an igen binding, hey can be less po en han he pa en mu ine monoclonal an ibodies
[21].Daclizumab, omalizumab, and alem uzumab a e examples o humanized an ibodies app o ed by he FDA [22].
1.3. Fully human MAbs
In addi ion, compa ed o using animal models, i is no p ac ical o immunize humans in i o wi h a wide a ie y o
an igens [23]. Simila ly, o sc een an ibody lib a ies, an ibody agmen s can be shown on ilamen ous bac e iophages
[24, 25]. The mos popula and well-es ablished app oach o c ea ing no el human an ibodies is he phage display
echnique [26].These consis o phage display pla o ms and ansgenic mice [27].
1.4. Fac o s A ec ing Pha macokine ics Pa ame e s
Pha macokine ics is s ill poo ly unde s ood, which makes i di icul o c ea e logical mAb he apy plans. A speci ic
mAb’s pha macokine ic p o ile migh be in luenced by a numbe o hings. Rapid clea ance may esul om ci cula ing
a ge an igens (28). In e naliza ion o an igen-an ibody Cells has an impac on hal -li e and se um clea ance.
Pha macokine ics can also be signi ican ly in luenced by an ibody size and domains in he Fc egion. Compa ed o hei
ull-sized pa en al o ms, mab agmen s usually ha e as e clea ance a es and sho e hal -li es. The ideal dosage and
iming o an ibody deli e y will also depend on he quan i y o a ge an igens ha a e a ailable and he binding a idi y
o he mAb. I is impo an o ake in o accoun addi ional ac o s pe aining o he modi ied ca bohyd a e side chains,
an ibody glycosyla ion, and an ibody ca abolism.
1.5. Ta ge an igen
When de eloping mAb-based ea men s, a ge an igen dis ibu ion is s ill a c i ical ac o o ake in o accoun (29, 32).
The he apeu ic po en ial o mAbs agains many an igens is comp omised because he majo i y o mAbs agains human
umo an igens bind no only o umo s bu also o no mal issues ha exp ess The an igen o a ge . Some o he shed
an igens seen in se um a e CA125 and CA19-9, ca cinoemb yonic an igen (CEA), p os a e speci ic an igen (PSA), TAG
72, and epide mal g ow h ac o ecep o (EGF-R). Ci cula ing an igens can be iden i ied in se um (29-32) Ci cula ing
umo an igens ha can bind o an ibodies in he bloods eam would nega i ely impac he apy by p e en ing he
a ge ing an ibody om eaching umo cells, as well as diagnos ic es s using adiolabeled an ibodies (33).Addi ionally,
as seen in pa ien s wi h B-cell lymphoma ea ed wi h adio labeled an i idio ypicmAbs, an igen shedding om he
umo cells’ su ace can esul in he c ea ion o ci cula ing immune complexes and quick emo al o he mAb om
blood (21).The ideal dosage and deli e y schedule o chime ic monoclonal an ibodies will also depend on he quan i y
o a ge an igens ha a e a ailable and he mAb’s binding ac i i y.
2. Conclusion
Monoclonal an ibodies a e ans o ming medicine. The p ecision hey o e in diagnosing and ea ing many diseases is
unma ched. These an ibodies ha e a unique abili y. They can speci ically a ge an igens.
These an ibodies a e p o ing i al in oncology. They also show p omise in au oimmune diso de s. Addi ionally hey a e
indispensable in managing in ec ious diseases. Bio echnology con inues o e ol e a a apid pace. This e olu ion is
inc easing hei e icacy. I is also educing side e ec s. I 's also b oadening hei he apeu ic use.
The e a e s umbling blocks. These include high p oduc ion cos s. Po en ial o esis ance is ano he obs acle. Ye he e
a e ongoing ad ancemen s in an ibody enginee ing. The e a e also inno a ions in deli e y sys ems. These ha e he
po en ial o su moun hese di icul ies.
We a e on he cusp o a new e a. Pe sonalized medicine is on he ho izon. Monoclonal an ibodies a e leading he way.
They a e a model o how ea men s can be cus omized. They can imp o e pa ien ou comes. They can make heal hca e
mo e ocused and e ec i e.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 083-087
86
Compliance wi h e hical s anda ds
Acknowledgemen s
Since es hanks go o he adminis a ion and acul y o K ishna Pha macy College. Thei con inued suppo was
ins umen al. They also con ibu ed g ea encou agemen h oughou his manusc ip . Special hanks a e ex ended o
ou colleagues. We a e g a e ul o hei in aluable insigh s. Thei guidance was uly bene icial. We acknowledge he
con ibu ions o all esea che s and o all au ho s, hei wo k has been e e enced. I is a key pa o his e iew.
Disclosu e o con lic o in e es
No con lic o in e es o be disclosed
Re e ences
[1] Kohle , G., Mils ein, C. Con inuous cul u es o used cells sec e ing an ibody o p ede ined speci ici y. Na u e
1975, 256: 495-7.
[2] Golds ein, N.I., P ewe , M., Zuklys, K., Rockwell, P., Mendelsohn, J. Biological e icacy o a chime ic an ibody o he
epide mal G ow h ac o ecep o in a human umo xenog a model. Clin Cance Res 1995, 1: 1311-8.
[3] Yang, X.D., Jia, X.C.J., Co alan, J.R.F., Wang, P., Da is, C.G. De elopmen o ABX-EGF, a ully human an i-EGF-R
monoclonal An ibody, o cance he apy. C i ical Re iews In Oncol And Hema 2001, 38: 17-23.
[4] C ombe , T., To es, L., Neninge , E. e al. Pha macological e alua ion o humanized an i-epide mal g ow h ac o
ecep o , monoclonal an ibody h-R3, in pa ien s wi h ad anced epi helial-de i ed Cance . J Immuno he 2003,
26: 139-48.
[5] Hna owich, D.J., Gione , M., Rusckowski, M. e al. Pha macokine ics o 111In-labeled OC-125 an ibody in cance
pa ien s compa ed wi h he 19-9 an ibody. Cance Res 1987, 47: 6111-7.
[6] Hna owich, D.J., G i in, T.W., Kosciuczyk, C. e al. Pha macokine ics o an indium-111-labeled monoclonal
an ibody in cance Pa ien s. J Nucl Med 1985, 26: 849-58.
[7] Poongodi V, Gopal KS, Raghuna han A. Monoclonal an ibody an upda ed e iew in den is y. In e na ional Jou nal
o Cu en Resea ch 2018;10:72408-72412.
[8] Ahmad ZA, Yeap SK, Ali AM, Ho WY, Ali heen NBM, Hamid M. scF An ibody: P inciples and Clinical Applica ion.
Clinical and De elopmen al Immunology 2012;2012:980250.
[9] Pece a S, Finco O, Seube A. Quan um leap o monoclonal an ibody (mAb) disco e y and De elopmen in he
COVID-19 e a. Semina s in Immunology 2020;50:101427.
[10] Hudson AJ, Sou iau C. Enginee ed an ibodies. Na u e Medicine 2003;9:124-132.
[11] Be ge M, Shanka V, Va ai A. The apeu ic Applica ions o Monoclonal An ibodies. Ame ican Jou nal o he
Medical Sciences 2002;324:14–30
[12] Nelson AL, Dhimolea E, Reiche JM. De elopmen T ends o human monoclonal an ibody he apeu ics. Na Re
D ug Disco e y 2010; 9(10): 767–774.
[13] Li J, Zhu Z. Resea ch and de elopmen o nex Gene a ion o an ibody-based he apeu ics. Ac aPha macol Sin
2010; 31(9): 1198–1207.
[14] Be ne MJ, Ka ki S, G Moo e GL, Leung IWL, Chen H, Pong E, Nguyen DHT, Jacin o J, Zale sky J, Muchhal US, e al.
Enginee ing Fully Human Monoclonal An ibodies om Mu ine Va iable Regions. J Mol Biol 2010; 396(5):1474–
1490
[15] Rod igues ME, Cos a AR, Hen ique M, Aze edo J, Oli ei a R. Technological p og esses in monoclonal An ibody
p oduc ion sys ems. Bio echnolP og 2010; 26(2): 332–351.
[16] B ezski RJ, Almag o JC. Applica ion o An ibody Enginee ing in he De elopmen o Nex Gene a ion An ibody-
Based The apeu ics. In De An ibody-Based The ap 2012; 4(29): 65-93
[17] O’B ien LM, Goodchild SA, Phillpo s RJ, Pe kins SD. A Humanised mu ine monoclonal an ibody p o ec s mice
F om Venezuelan equine encephali is i us, E e glades Vi us and Mucambo i us when adminis e ed up o 48h
A e ai bo ne challenge. Vi ology 2012; 426(2): 100–105.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 083-087
87
[18] Lin W, Ku osawa K, Mu ayama A, Kagaya E, Oh a K. Bcell display-based one-s ep me hod o gene a e chime ic
human IgG monoclonal an ibodies. Nucleic Acids Res 2011; 39(3): 1–10
[19] Mak TM, Hanson BJ, Tan YJ. Chime iza ion and Cha ac e iza ion o a monoclonal an ibody wi h po en
Neu alizing ac i i y ac oss mul iple in luenza A H5N1 Clades. An i i al Res 2014; 107(1): 76–83
[20] Wang S. Ad ances in he p oduc ion o human Monoclonal an ibodies. An ibTechnol J 2011; 1: 1–4.
[21] Chandel P, Ha ikuma SL. Pha maceu ical monoclonal An ibodies: P oduc ion, guidelines o cell enginee ing And
applica ions. In J Pha m Pha ma Sci 2013; 5(2):13–20
[22] Ha ding FA, S ickle MM, Razo J, DuB idge RB. The Immunogenici y o humanized and ully human An ibodies:
Residual immunogenici y esides in he CDR Regions. MAbs 2010; 2(3): 256–265.
[23] Be ne MJ, Ka ki S, G Moo e GL, Leung IWL, Chen H, Pong E, Nguyen DHT, Jacin o J, Zale sky J, Muchhal US, e al.
Enginee ing Fully Human Monoclonal An ibodies om Mu ine Va iable Regions. J Mol Biol 2010; 396(5):1474–
1490.
[24] S eini z M. Human Monoclonal An ibodies. In Me hods in Molecula biology (Cli on, N.J.), 2014; 1060: 111–22.
[25] Medecigo M, Manou cha ian K, Vasile ko V, Go ezensky T, Munguia ME, Bece il B, Luz-Mad igal A, Vaca L, C ibbs
DH, Ge o kian G. No el amyloid-be a speci ic scF and VH an ibody agmen s om human and mouse phage
display an ibody lib a ies. J Neu oimmunol 2010; 223(1): 104–114.
[26] Sol o osi L, Mancini N, Canducci F, Clemen i N, Sau o GA, Dio i RA, Clemen i M, Bu ioni R. A phage display Vec o
op imized o he gene a ion o human an ibody Combina o ial lib a ies and he molecula cloning o Monoclonal
an ibody agmen s. New Mic obiol 2012; 35(3):289–294.
[27] Chandel P, Ha ikuma SL. Pha maceu ical monoclonal An ibodies: P oduc ion, guidelines o cell enginee ing And
applica ions. In J Pha m Pha ma Sci 2013; 5(2):13–20.
[28] Ca asquillo, J.A., Colche , D., Suga bake , P. e al. Radioimmunoscin ig aphy o colon cance wi h Iodine-131
labeled B72.3 monoclonal an ibody. J Nucl Med 1988, 29: 1022-30.
[29] 17. Ca asquillo, J.A., Colche , D., Suga bake , P. e al. Radioimmunoscin ig aphy o colon cance wi h Iodine-131
labeled B72.3 monoclonal an ibody. J Nucl Med 1988, 29: 1022-30.
[30] Baselga, J., P is e , D., Coope , M.R. e al. Phase I s udies o an iepide mal g ow h ac o ecep o chime ic
an ibody C225 aloneand in combina ion wi h cispla in. J Clin Oncol 2000, 18: 904-14.
[31] Iznaga-Escoba , N., To es, L., Mo ales, A. e al. 99mTc-labeled an iEGF- ecep o an ibody in pa ien s wi h umo
o epi helial o igin:I. Biodis ibu ion and dosime y o adioimmuno he apy. J Nucl Med 1998, 39: 15-23.
[32] Goldenbe g, D.M., Deland, F.H. His o y and S a us o umo imaging wi h adiolabeled an ibodies. J Biol Response
Modi 1983, 1:121-36.
